Tomoko Takano, MS, RN, CNS | |
1520 Los Montes Dr, Burlingame, CA 94010-5964 | |
(248) 703-4518 | |
Not Available |
Full Name | Tomoko Takano |
---|---|
Gender | Female |
Speciality | Clinical Nurse Specialist |
Location | 1520 Los Montes Dr, Burlingame, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134697238 | NPI | - | NPPES |
4754 | Other | CA | CLINICAL NURSE SPECIALIST |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
364S00000X | Clinical Nurse Specialist | 4754 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Tomoko Takano, MS, RN, CNS 1520 Los Montes Dr, Burlingame, CA 94010-5964 Ph: (248) 703-4518 | Tomoko Takano, MS, RN, CNS 1520 Los Montes Dr, Burlingame, CA 94010-5964 Ph: (248) 703-4518 |
News Archive
Having bad breath can mean someone ate a smelly lunch, but it could indicate that the person is sick. Various scent compounds have been linked to illnesses such as diabetes, lung cancer and Parkinson's disease, leading scientists to develop technology that measures these substances.
Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.
Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.
Cataract surgery can benefit patients with exudative age-related macular degeneration previously treated with anti-vascular endothelial growth factors if they have been treated and are exudation-free for more than 12 months, study findings indicate.
› Verified 8 days ago